. Author manuscript; available in PMC: 2015 Jan 1.

Published in final edited form as: Aliment Pharmacol Ther. 2013 Nov 17;39(2):10.1111/apt.12553. doi: 10.1111/apt.12553

Table 3.

Interventional studies examining the effect of vitamin D supplementation on disease activity in Crohn’s disease and ulcerative colitis

Author	Year	Study Design	Number of patients	Intervention	Outcome	Result
Miheller⁸⁰	2009	Open label	37 patients with inactive CD	Daily 0.5mcg of alfacalcidiol or 1000 IU of cholecalciferol	CDAI	Mean CDAI decreased from 69 to 57 in patients treated with alfacalcidiol
Jorgensen¹²	2010	Randomized placebo- controlled trial	104 CD patients in clinical remission	Oral vitamin D3 1200 IU daily or placebo	Relapse	Relapse rate was lower in patients treated with vitamin D3 (13%) compared to placebo (29%) (p=0.06)
Yang⁸¹	2013	Open label	18 patients with mild-to-moderate CD	Vitamin D3 at 1,000 IU daily; dose increase after 2 weeks to achieved serum 25(OH)D of 40ng/mL	CDAI Quality of life	Vitamin D supplementation reduced CDAI scores from 230 to 118 (p < 0.0001), and improved health related quality of life

CD – Crohn’s disease; CDAI –crohn’s disease activity index;